Japan Palmoplantar Pustulosis (PPP) Market – Industry Trends and Forecast to 2030

Japan Palmoplantar Pustulosis (PPP) Market, By Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Diagnosis (Laboratory Tests, Skin Biopsy), Treatment (Emollients, Topical Steroids, Coal tar, Phototherapy), Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Japan Palmoplantar Pustulosis (PPP) Market Analysis and Size

Growing incidence of palmoplantar pustulosis and increasing women population are the primary factors that boosted the market demand in the forecast period 2023-2030. Several research stated that up to 90% of people suffering from the skin condition, smoke or once did. The accurate cause of palmoplantar pustulosis is not known. This disease can occur in any age group. But mostly it occurs in women than men, and it's most frequently found in people between the age group of 40 and 60 years. The majority of patients suffering from palmoplantar pustulosis are seen to be current smokers and in those that have smoked in the past (65–90%).

Data Bridge Market Research analyses a growth rate in the palmoplantar pustulosis (PPP) market in the forecast period 2023-2030. The expected CAGR of palmoplantar pustulosis (PPP) market is tend to be around 6.3% in the mentioned forecast period. The market is valued at USD 135.9 million in 2022, and it would grow upto USD 221.6 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Japan Palmoplantar Pustulosis (PPP) Market Scope and Segmentation

Market Definition

Palmoplantar pustulosis is a type of uncommon chronic pustular condition affecting the palms and soles. It is associated to a common skin condition, psoriasis. Palmoplantar pustulosis have symptoms such as crops of sterile pustules occurring on one or both hands and feet. They are associated with thickened, red, scaly skin that easily develops painful cracks. Palmoplantar pustulosis varies in severity and may persist for many years. The discomfort can be considerable, interfering with work and leisure activities.   

Japan Palmoplantar Pustulosis (PPP) Market Dynamics

Drivers

• Availability of Diverse Treatments for PPP

Numerous treatment options are useful for treating patients suffering from PPP. Light therapy is a treatment that combines a medicine known as psoralen with a special form of ultraviolet light. Other treatments such as retinoids, biologic treatmnets such as adalimumab (Humira), brodalumab (Siliq), certolizumab pegol (Cimzia) etanercept (Enbrel). Other options include enzyme inhibitor, Methotrexate aryl hydrocarbon receptor (AHR) agonist are also useful. Thus, all these treatment options help in faster recovery of the patients impacting the market growth positively.

• Increasing Agreements and Product Launches by Different Market Players

There have been a growing number of agreements and product approvals different market players is expected to increase the market growth. For instance, Zydus Pharmaceuticals, Inc. received final approval for Clobetasol Propionate Cream in 2018, specifically indicated for treatment of inflammatory symptoms associated with skin diseases. This topical cream is largely used for treatment of mild to moderate palmoplantar pustulosis. Also, in 2016, Teva Pharmaceutical Industries Ltd. acquired Allergan’s Anda Inc. with the aim to expand its generic product portfolio used for the treatment of palmoplantar pustulosis among others. Thus, this factor boosts the market growth.

Opportunities

• Increasing Demand For Topical Steroids

Topical steroids are widely used in the treatment of palmoplantar pustulosis. Topical steroids are the type of anti-inflammatory agents which range in potency and vehicle. Only the strongest ointments are highly effective for thick skin of the hands and feet. Although, the very potent products such as clobetasol propionate should be only used only for limited periods or else side effects and loss of efficacy become a problem. The effect may be improved by using plastic obstruction for a few hours or even overnight. Thus, this factor increases the market growth.

• Rising Demand of Parenteral Administration

The parenteral route of administration is increasing the market growth because parenteral formulations directly reaches to systemic circulation and have more efficacy. Furthermore, biological therapies are widely available in injectable formulation. This type of administration has several advantages, such as better bioavailability, first-pass metabolism avoidance, and reliable dosage. Thus, this factor increases the market growth.

Restraints/Challenges

• Increased Expenditure of Treatment for PPP

The rising expenditure associated with the varied treatment and diagnostic options of PPP hinder the market growth. This disease demands prolonged treatment many a times which increases the overall cost which is not that feasible for people belonging to underdeveloped and developing regions. This impedes the market growth.

This palmoplantar pustulosis (PPP) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the palmoplantar pustulosis (PPP) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Japan Palmoplantar Pustulosis (PPP) Market Scope

The palmoplantar pustulosis (PPP) market is segmented on the basis of disease type, severity, diagnosis, treatment, population type, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type  

• Type A
• Type B

Severity

• Mild-Moderate
• Moderate-Severe 

Diagnosis

• Laboratory Tests
• Skin Biopsy

Treatment

• Emollients
• Topical Steroids
• Coal tar
• Phototherapy

Population Type

• Children
• Adults

Route of Administration

• Oral
• Topical
• Parenteral

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Competitive Landscape and Japan Palmoplantar Pustulosis (PPP) Market Share Analysis

The palmoplantar pustulosis (PPP) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Japan presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to palmoplantar pustulosis (PPP) market

Key players operating in the palmoplantar pustulosis (PPP) market include:

• Novartis AG (Switzerland)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Amgen inc. (U.S.)
• AnGes, Inc. (Japan)
• Johnson & Johnson Private Limited (U.S.)
• AbbVie Inc. (U.S.)
• Perrigo Company plc (Ireland)
• WOCKHARDT (India)
• Bausch Health Companies Inc.(Canada)
•  Viatris Inc. (U.S.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Xiromed (U.S.)
• Encube Ethicals Private Limited (U.S.)